Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat
- PMID: 20466656
- DOI: 10.1093/ndt/gfq230
Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat
Abstract
Background: To date, no effective immunosuppressive standard for the prevention or treatment of alloantibody production in acute and chronic rejection of renal transplants has been established. Alloantibody formation has been recognized in the well-established rat model of Fischer to Lewis renal transplantation. We used this renal allotransplantation model to test the effectiveness of sirolimus (SRL), bortezomib (BZ) or their combination in an already established humoral rejection situation.
Methods: After 3 weeks, transplanted rats were treated either with placebo (P), SRL, BZ or combination of SRL and BZ. Rats were monitored for donor-specific alloantibodies as well as humoral responses in the spleen and bone marrow, renal function and histological changes in the graft.
Results: In all three treatment arms, glomerular, tubulointerstitial and vascular changes of chronic antibody-mediated rejection were ameliorated compared to the P group. Production of alloantibodies against components of glomerular basement membrane was reduced in all three treatment arms. The humoral response was strongly reduced, as shown by decreased numbers of IgG-secreting cells, plasma cells and partially B cells in all treatment groups with a trend of SRL/BZ combination being most effective. Infiltration of the graft with inflammatory cells like cytotoxic T cells, T helper cells, B cells and macrophages was efficiently blocked by BZ and the SRL/BZ combination and, except for B cells, by SRL.
Conclusions: BZ and SRL represent promising drugs with anti-humoral activity in the situation of an already established chronic humoral or mixed alloimmune response after renal transplantation.
Similar articles
-
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.Transplantation. 2008 Dec 27;86(12):1754-61. doi: 10.1097/TP.0b013e318190af83. Transplantation. 2008. PMID: 19104417
-
Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.Clin Transpl. 2009:455-9. Clin Transpl. 2009. PMID: 20524314 No abstract available.
-
Bortezomib for acute humoral rejection in two repeat transplant recipients.Clin Transpl. 2009:479-83. Clin Transpl. 2009. PMID: 20524319
-
Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.Exp Clin Transplant. 2012 Aug;10(4):406-9. doi: 10.6002/ect.2011.0153. Epub 2012 Jun 29. Exp Clin Transplant. 2012. PMID: 22746156 Review.
-
Proteasome inhibition for antibody-mediated rejection.Curr Opin Organ Transplant. 2009 Dec;14(6):662-6. doi: 10.1097/MOT.0b013e328330f304. Curr Opin Organ Transplant. 2009. PMID: 19667989 Review.
Cited by
-
Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-α-Smurf1-Akt-mTOR-P70S6K pathway.J Cell Mol Med. 2019 Aug;23(8):5390-5402. doi: 10.1111/jcmm.14420. Epub 2019 May 29. J Cell Mol Med. 2019. PMID: 31140729 Free PMC article.
-
Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy.Cell Biochem Biophys. 2015 Jan;71(1):457-64. doi: 10.1007/s12013-014-0224-x. Cell Biochem Biophys. 2015. PMID: 25343940 Free PMC article. Clinical Trial.
-
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484. World J Gastroenterol. 2016. PMID: 27605883 Free PMC article. Review.
-
Impact of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Rat Model of Kidney Rejection.Front Cell Dev Biol. 2020 Jan 29;8:10. doi: 10.3389/fcell.2020.00010. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32064259 Free PMC article.
-
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.Genes Immun. 2020 Nov;21(5):273-287. doi: 10.1038/s41435-020-00109-1. Epub 2020 Aug 25. Genes Immun. 2020. PMID: 32839530 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous